Miraculins

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Miraculins yesterday said that it has received a C$1 million (US$986,000) non-convertible secured loan from Gretchen Ross.

The company said that if all warrants are exercised on or before expiration of the early exercise period, Miraculins expects to receive gross proceeds of around C$780,000.

Bloom Burton will provide financial modeling, an assessment of financing options, an evaluation of partnership opportunities, and other services.

The biomarker-based diagnostics firm sold 10.2 million units at C$.05 each.

The biomarker-based diagnostics firm will use the placement funding for R&D and corporate purposes.

Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.

Miraculins will work with the Israel-based firm on a program to develop biomarker-based diagnostics for determining preeclampsia risk.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.